EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies

Petar Brlek iD, Vedrana Škaro iD, Nenad Hrvatin iD, Luka Bulić iD, Ana Petrović iD, Petar Projić, Martina Smolić iD, Parth Shah, Dragan Primorac iD

Cancers · 30.10.2025 · 17 (21) · 3500

DOI: 10.3390/cancers17213500 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.10.2025. Verfasst von Petar Brlek und 8 weiteren Autor:innen. Beteiligte Einrichtung: St. Catherine Specialty Hospital, 10000 Zagreb, Croatia. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid evolution of sequencing technologies has profoundly advanced precision oncology. Whole-exome sequencing (WES), whole-genome sequencing (WGS), and whole-transcriptome sequencing (RNA-Seq) enable comprehensive characterization of tumor biology by detecting actionable mutations, gene fusions, splice variants, copy number alterations, and pathway dysregulation. These approaches also provide critical insights into biomarkers such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI), which are increasingly essential for guiding therapeutic decisions. Importantly, comprehensive genomic profiling not only refines patient stratification for targeted therapies but also sheds light on tumor–immune interactions and the tumor microenvironment, paving the way for more effective immunotherapeutic combinations. WGS is considered the gold standard for detecting germline mutations and complex structural variants, while WES remains central for detecting somatic driver mutations that guide targeted therapies. RNA-Seq complements these methods by capturing gene expression dynamics, identifying clinically relevant fusions, and revealing mechanisms of resistance. Together with advances in bioinformatics and artificial intelligence, these tools translate molecular data into actionable strategies for patient care. This review integrates insights from WGS, WES, and RNA-Seq with an overview of FDA- and EMA-approved targeted therapies, organized by tumor type, and highlights the molecular signaling pathways that drive cancer development and treatment. By bridging genomic profiling with regulatory-approved therapies, we outline current advances and future perspectives in delivering personalized cancer care.

Schlagwörter

Stichwörter der Autor:innen

RNA sequencingartificial intelligenceimmunotherapypersonalized medicineprecision oncologywhole-genome sequencing

Autor:innen und Institutionen

  • St. Catherine Specialty Hospital, 10000 Zagreb, Croatia.
  • International Center for Applied Biological Research, 10000 Zagreb, Croatia.
  • Department of Molecular Biology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia.
  • School of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
  • Department of Pediatrics, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.
  • Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.

ORCID-Profile: Petar Brlek, Vedrana Škaro, Nenad Hrvatin, Luka Bulić, Ana Petrović, Martina Smolić, Dragan Primorac

Zitieren

APA

Brlek, P., Škaro, V., Hrvatin, N., Bulić, L., Petrović, A., Projić, P., Smolić, M., Shah, P., & Primorac, D. (2025). Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies. Cancers, 17(21), 3500. https://doi.org/10.3390/cancers17213500

Vancouver

Brlek P, Škaro V, Hrvatin N, Bulić L, Petrović A, Projić P, et al. Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies. Cancers. 2025;17(21):3500. doi:10.3390/cancers17213500

BibTeX
@article{Brlek2025,
  author = {Brlek, Petar and Škaro, Vedrana and Hrvatin, Nenad and Bulić, Luka and Petrović, Ana and Projić, Petar and Smolić, Martina and Shah, Parth and Primorac, Dragan},
  title = {Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {21},
  pages = {3500},
  doi = {10.3390/cancers17213500}
}
Kostenlos starten →